相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival
Michael Ozga et al.
CANCER MEDICINE (2021)
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
Giovanni Palladini et al.
BLOOD CANCER JOURNAL (2021)
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
E. Kastritis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
Sriram Ravichandran et al.
BLOOD CANCER JOURNAL (2021)
Epidemiologic and Survival Trends in Amyloidosis, 1987-2019
Sriram Ravichandran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival
Amandeep Godara et al.
BLOOD (2019)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
Richa Manwani et al.
BLOOD (2019)
What does minimal residual disease mean in AL amyloidosis?
Paolo Milani et al.
EXPERT OPINION ON ORPHAN DRUGS (2018)
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study
Tilmann Bochtler et al.
BLOOD (2016)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
Joseph R. Mikhael et al.
BLOOD (2012)
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
Christopher P. Venner et al.
BLOOD (2012)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)